Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals
Executive Summary
Merck’s Keytruda may nevertheless have the stronger market position given its broader and stronger labeling in second-line endometrial cancer and strong position in women’s oncology overall.
You may also be interested in...
GSK's Jemperli First-Line Endometrial Cancer Approval Fillip Ahead Of Keytruda Advance
The major’s PD-L1 inhibitor is the first to win US approval for the treatment of first-line endometrial cancer in combination with chemotherapy, but an unsurprisingly narrow label means rival Merck & Co.’s Keytruda could still make a splash in this indication.
Merck’s Keytruda Further Entrenches Women’s Oncology Position With Cervical Cancer Results
Merck said the KEYNOTE-A18 trial in newly diagnosed, high-risk locally advanced patients met its PFS co-primary endpoint, while results for the OS endpoint were not yet mature.
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.